Company news
Futura Medical Plc (LSE:FUM) news
Futura Medical Plc news releases on 6ix. Latest, Sep 11, 2024: Trinity Delta research note & consensus forecasts
Press releases — page 2
Trinity Delta research note & consensus forecasts
September 11, 2024
Futura Medical - Interim Results 2024
September 10, 2024
Update on US Launch
September 2, 2024
Notice of Results
August 19, 2024
Update on US launch
August 1, 2024
Nominated Adviser and Joint Broker
July 1, 2024
AGM Statement
June 20, 2024
Block Listing Six Monthly Review
May 31, 2024
Directors’ / PDMR Dealing and Grant of Options
April 29, 2024
Futura Medical targets global expansion with Eroxon, eyeing profitability in 2024
April 11, 2024
Results for the Year ended 31 December 2023
April 10, 2024
Eroxon to be available on prescription
February 14, 2024
Futura Medical marks pivotal year with first meaningful revenue from Eroxon sales
February 8, 2024
Appointment of Joint Corporate Broker
February 6, 2024
Director/PDMR Dealing
January 17, 2024
Futura Medical extends collaboration with Cooper
January 15, 2024
Appointment of Roy Davis as Non-Executive Director
January 9, 2024
Futura expands partnership with M8 Pharmaceuticals
November 7, 2023
Eroxon Awarded “New Product of the Year” by Boots
November 2, 2023
Block Listing Application and Total Voting Rights
October 31, 2023
Eroxon® Granted Marketing Authorisation in Mexico
October 25, 2023
Eroxon Launches in the United Arab Emirates
October 19, 2023
Directors’/PDMR Dealing and Grant of Options
October 10, 2023
European Patent Granted for MED3000 until 2040
October 2, 2023
Futura Medical - Interim Results 2023
September 18, 2023
Futura Medical - Notice of Interim Results
August 18, 2023
MED3000 Commercialisation Approval in Saudi Arabia
August 9, 2023
Futura Medical - Total Voting Rights
July 31, 2023
Futura Medical "absolutely delighted" with US commercialisation agreement
July 19, 2023
Board Change
July 18, 2023
Futura/Haleon Enter US Commercialisation Agreement
July 17, 2023
Recording of Investor Seminar
June 23, 2023
Futura Medical Annual General Meeting Results
June 22, 2023
Correction - TR-1: Notification of major holdings
June 19, 2023
Exercise of Warrants
June 12, 2023
Futura Medical Announces Investor Seminar
June 8, 2023
MED3000, Eroxon® UK Launch
April 18, 2023
Directors' / PDMR Dealing and Grant of Options
April 6, 2023
Full Year Results ended 31 December 2022
April 5, 2023
Update on MED3000 regulatory approval in the US
March 29, 2023
Notice of Preliminary Results 2022
March 27, 2023
MED3000 commercial and US regulatory update
March 14, 2023
MED3000 FM71 Presentation at ESSM Congress 2023
February 15, 2023
Block Listing Applications to AIM
February 1, 2023
Pre-launch of MED3000 ahead of H1 2023 launch
January 26, 2023
Futura Remuneration, Options & Total Voting Rights
January 12, 2023
Futura Medical 'on track' for launch in H1 2023
December 13, 2022
Futura Block Listing Six Monthly Return
November 30, 2022
Second Price Monitoring Extn
October 21, 2022
Application to the US FDA for MED3000
October 3, 2022